NETRIS Pharma announces data published in two Nature papers

• Anti-netrin-1 monoclonal antibody, NP137, demonstrates objective response and disease stabilization as monotherapy in Phase 1 study of patients with advanced endometrial carcinoma (EC); effective in inhibiting tumor growth in several different preclinical mouse models.

• Paired biopsies, pre-and-on NP137 treatment, highlight a statistically significant reduction of tumor epithelial-to-mesenchymal transition.

• Netrin-1 blockade with NP137, is confirmed as a clinical strategy to alleviate resistance to standard treatments, in multiple clinical indications, including EC.

LYON, France — NETRIS Pharma, a clinical-stage biopharmaceutical company developing first-in-class anticancer drugs, today announced data showing that its lead compound, NP137, is effective in reducing tumor growth and inhibiting tumor epithelial-to-mesenchymal transition (EMT). These data were published in Nature as two back-to-back papers titled “Pharmacological targeting netrin-1 inhibits EMT in cancer” and “Netrin-1 blockade inhibits tumor growth and EMT features in endometrial cancer,” as well as a clinical briefing: “Blockade of netrin-1 is a promising strategy against endometrial cancer”.

Read the press release